

# Phathom<sup>®</sup>

## PHARMACEUTICALS

### Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

November 3, 2025

FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences:

**Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA**

Date: Monday, November 10, 2025

Live Webcast: 3:00 pm EST

*Management to participate in one-on-one meetings throughout the conference*

**Stifel 2025 Healthcare Conference in New York, NY**

Date: Wednesday, November 12, 2025

Live Webcast: 4:40 pm EST

*Management to participate in one-on-one meetings throughout the conference*

**Jefferies Global Healthcare Conference in London, UK**

Date: Tuesday, November 18, 2025

Live Webcast: 9:30 am EST / 2:30 pm GMT

*Management to participate in one-on-one meetings throughout the conference*

**16th Annual Craig-Hallum Alpha Select Conference in New York, NY**

Date: Tuesday, November 18, 2025

*Management to participate in one-on-one meetings throughout the conference*

**8th Annual Evercore Healthcare Conference in Miami, FL**

Date: Tuesday, December 2, 2025

Live Webcast: 3:25 pm EST

*Management to participate in one-on-one meetings throughout the conference*

To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. Recordings will be available for 90 days following the conclusion of each meeting.

**About Phathom Pharmaceuticals, Inc.**

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA<sup>®</sup> (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of the VOQUEZNA<sup>®</sup> TRIPLE PAK<sup>®</sup> (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA<sup>®</sup> DUAL PAK<sup>®</sup> (vonoprazan tablets, amoxicillin capsules) for the treatment of *H. pylori* infection in adults. For more information about Phathom, visit the company's website at [www.phathompharma.com](http://www.phathompharma.com) and follow on [LinkedIn](#) and [X](#).

**MEDIA CONTACT**

Nick Benedetto

1-877-742-8466

[media@phathompharma.com](mailto:media@phathompharma.com)

**INVESTOR CONTACT**

Eric Sciorilli

1-877-742-8466

[ir@phathompharma.com](mailto:ir@phathompharma.com)

